Estrela Immunopharma, Inc. (Nasdaq: Esla; Eslaw) gets a purchase assessment with a target price of 12 months from $ 16.00 from D. Boral Capital

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.